Neurology Book

http://www.fpnotebook.com/

PrimidoneAka: Mysoline

Advertisement

  1. Indications
    1. Seizure disorder
      1. Grand Mal Seizure
      2. Psychomotor Seizure
      3. Focal Seizure
    2. Essential Tremor
  2. Contraindications
    1. Porphyria
    2. Phenobarbital hypersensitivity
  3. Mechanism
    1. Barbiturate with 2 active metabolites
      1. Phenobarbital
      2. Phenylethylmalonamide (PEMA)
    2. Raises Seizure threshold
  4. Dosing: adults and children over age 8 years
    1. Titration to maintenance dose
      1. Days 1 to 3: Take 100-125 mg PO qhs
      2. Days 4 to 6: Take 100-125 mg PO bid
      3. Days 7 to 9: Take 100-125 mg PO tid
      4. Days >10: Take 250 mg PO tid
    2. Maintenance dosing
      1. Standard dosing: 250 mg PO tid-qid
      2. Maximum dosing: 500 mg PO qid (do not exceed)
  5. Monitoring: Labs every 6 months
    1. Complete Blood Count
    2. Chemistry panel (SMA-12)
  6. Adverse effects
    1. Common
      1. Ataxia
      2. Vertigo
    2. Occasional
      1. Nausea, Vomiting or anorexia
      2. Fatigue or drowsiness
      3. Hyperirritability or other emotional disturbance
      4. Sexual Impotence
      5. Diplopia or Nystagmus
      6. Morbilliform skin rash
    3. Rare
      1. Megaloblastic Anemia responsive to folate

Primidone (C0033148)

Definition (MSH)An antiepileptic agent related to the barbiturates; it is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite. Adverse effects are reported to be more frequent than with PHENOBARBITAL. (From Martindale, The Extra Pharmacopoeia, 30th ed, p309)
Definition (NCI)An analog of phenobarbital with antiepileptic property. Although the mechanism of action has not been fully elucidated, primidone probably exerts its actions, in a manner similar to phenobarbital, via activation of gamma-aminobutyric acid (GABA)-A receptor/chloride ionophore complex, which leads to prolonged and increased frequency of opening of the chloride channel within the receptor complex. This results in an alteration in the electrical activity of the nerve cell membrane, causing hyperpolarization and prevention of partial and tonic-clonic seizures. In addition, this agent is partially metabolized to phenobarbital and phenylethylmalonamide (PEMA), which may also contribute to its anti-seizure properties.
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD011324
English2-Deoxyphenobarbital, Desoxyphenobarbital, Hexamidinum, Misodine, Mysedon, Primidone, PRIMIDONE PREPARATION, Primidone product
Spanishdesoxifenobarbital, primidona
Parent ConceptsBarbiturates (C0004745), Phenobarbital (C0031412), Anticonvulsants (C0003286), Barbiturate antiepileptic (C0360117), Duplicate concept (C1274013), Deoxybarbiturate (C1628315), Gamma-aminobutyric Acid (GABA) Augmenting Agents (C1579354)
SourcesAOD, CSP, LNC, MSH, MTH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Mysoline (C0700016)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD011324
EnglishAstra Brand of Primidone, AstraZeneca Brand of Primidone, Draxis Brand of Primidone, Mylepsinum, Mysoline, Xcel Brand of Primidone, Zeneca Brand of Primidone
SourcesMSH, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree